Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,424 | -56,700 | -53,853 | -52,622 | -50,340 |
| Depreciation Amortization | 1,796 | 55,218 | 53,244 | 51,563 | 49,737 |
| Income taxes - deferred | -85 | -680 | -553 | -573 | -523 |
| Accounts receivable | 1,406 | -934 | 3,022 | 3,232 | 1,438 |
| Accounts payable and accrued liabilities | 1,181 | 2,300 | 1,503 | 1,774 | 1,472 |
| Other Working Capital | 794 | 5,673 | 6,591 | 6,301 | 3,512 |
| Other Operating Activity | -2,330 | 1,852 | -3,129 | -3,934 | -2,310 |
| Operating Cash Flow | $-662 | $6,729 | $6,825 | $5,741 | $2,986 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -426 | -1,258 | -809 | -602 | -513 |
| Purchase Sale Intangibles | -194 | -605 | -455 | -314 | -170 |
| Other Investing Activity | -194 | -605 | -455 | -314 | -170 |
| Investing Cash Flow | $-620 | $-1,863 | $-1,264 | $-916 | $-683 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 40,000 | N/A | N/A | N/A |
| Debt Repayment | N/A | -37,350 | N/A | -2,000 | -1,000 |
| Common Stock Issued | 150 | 47 | 46 | 46 | N/A |
| Other Financing Activity | -159 | -3,988 | -3,786 | -508 | -204 |
| Financing Cash Flow | $-9 | $-1,291 | $-3,740 | $-2,462 | $-1,204 |
| Exchange Rate Effect | -225 | 931 | 888 | 971 | 339 |
| Beginning Cash Position | 8,614 | 4,108 | 4,108 | 4,108 | 4,108 |
| End Cash Position | 7,098 | 8,614 | 6,817 | 7,442 | 5,546 |
| Net Cash Flow | $-1,516 | $4,506 | $2,709 | $3,334 | $1,438 |
| Free Cash Flow | |||||
| Operating Cash Flow | -662 | 6,729 | 6,825 | 5,741 | 2,986 |
| Capital Expenditure | -426 | -1,258 | -809 | -602 | -513 |
| Free Cash Flow | -1,088 | 5,471 | 6,016 | 5,139 | 2,473 |